Benevir Biopharm

Benevir Biopharm

Benevir Biopharm

In the emerging field of oncolytic virotherapy, BeneVir is developing an improved therapeutic platform that can be adapted to target a wide variety of cancers.
Founded
2011
Raised
$5M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$3,000,000
Venture capital - 2016
$2,000,000
Venture capital - 2014
Team Size
1–10
Employees

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when Benevir Biopharm makes some noise.